Genetic testing for thrombophilia mutations

Area of Science:

• Medical Genetics
• Hematology
• Molecular Diagnostics

Background:

• Venous thrombosis is a complex condition influenced by genetic and environmental factors.
• Common genetic risk factors, including factor V Leiden and prothrombin G20210A mutations, are prevalent in the population.
• Laboratory diagnostics for thrombophilic disorders have evolved to include molecular assays for precise identification of genetic mutations.

Purpose of the Study:

• To discuss the implications of genetic testing for venous thrombosis.
• To highlight the advantages of molecular assays over functional assays.
• To outline patient management considerations and DNA methodology selection criteria.

Main Methods:

• Review of current molecular diagnostic techniques for thrombophilic mutations.
• Discussion of criteria for selecting DNA methodologies (cost, automation, speed, reliability, simplicity).
• Exploration of emerging technologies like real-time polymerase chain reaction and DNA microarrays.

Main Results:

• Molecular assays provide unequivocal results for genetic mutations, unlike functional assays.
• Identification of genetic risk factors impacts decisions on anticoagulant therapy, prophylaxis, and family studies.
• Real-time PCR and DNA microarrays show promise for future widespread application.

Conclusions:

• Molecular testing is crucial for managing patients with venous thrombosis and inherited thrombophilia.
• The choice of DNA methodology should balance technical performance with practical considerations.
• Advanced molecular technologies are poised to enhance the diagnosis and management of thrombotic disorders.